Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024
March 05, 2024 12:00 ET
|
Phaxiam Therapeutics S.A.
Monthly information related to total number of voting rights and shares composing the share capital - February 29, 2024 Article 223-16 of general regulation of French Autorité des Marchés...
PHAXIAM Therapeutics annonce son intention de procéder au retrait volontaire de ses « American Depositary Shares » du Nasdaq Capital Market
February 20, 2024 16:05 ET
|
Phaxiam Therapeutics S.A.
PHAXIAM reste cotée sur Euronext Paris, son marché principal Le retrait de la cote du Nasdaq réduira considérablement la consommation de trésorerie de PHAXIAM et permettra à la Société de concentrer...
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market
February 20, 2024 16:05 ET
|
Phaxiam Therapeutics S.A.
PHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital Market PHAXIAM remains listed on Euronext Paris as its primary trading marketNasdaq...
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2024
February 06, 2024 16:05 ET
|
Phaxiam Therapeutics S.A.
Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers Places de cotation : Euronext Paris de Euronext (Compartiment C - Code ISIN : FR001400K4B1 – Symbole : PHXM) &...
Monthly information related to total number of voting rights and shares composing the share capital - January 31, 2024
February 06, 2024 16:05 ET
|
Phaxiam Therapeutics S.A.
Article 223-16 of general regulation of French Autorité des Marchés Financiers Listing markets: Euronext Paris from Euronext (Market segment C - ISIN Code: FR001400K4B1- Symbol: PHXM) &...
PHAXIAM Therapeutics annonce son niveau de trésorerie à fin 2023 et son calendrier financier 2024
January 18, 2024 16:05 ET
|
Phaxiam Therapeutics S.A.
Lyon (France) et Cambridge (MA, US), le 18 janvier 2024 – 22h05 CET – PHAXIAM Therapeutics (Nasdaq & Euronext : FR0011471135), annonce aujourd’hui sa trésorerie au 31 décembre 2023 et son...
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024
January 18, 2024 16:05 ET
|
Phaxiam Therapeutics S.A.
Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe...
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2023
January 03, 2024 16:05 ET
|
Phaxiam Therapeutics S.A.
Information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 décembre 2023 Article 223-16 du Règlement Général de l’Autorité des Marchés...
Monthly information related to total number of voting rights and shares composing the share capital - December 31, 2023
January 03, 2024 16:05 ET
|
Phaxiam Therapeutics S.A.
Monthly information related to total number of voting rights and shares composing the share capital _ December 31, 2023 Article 223-16 of general regulation of French Autorité des Marchés...
Monthly information related to total number of voting rights and shares composing the share capital - November 30, 2023
December 06, 2023 16:05 ET
|
Phaxiam Therapeutics S.A.
Monthly information related to total number of voting rights and shares composing the share capital _ November 30, 2023 Article 223-16 of general regulation of French Autorité des Marchés...